On Wednesday, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said it is cutting the annual list price of its triglyceride-lowering drug Tryngolza (olezarsen) to $40,000 from $595,000. The move positions the therapy more competitively ahead of a potential label expansion into severe hypertriglyceridemia (sHTG) later this year.

Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.

The revised wholesale acquisition cost (WAC) will take effect on April 1.

The drug is currently approved for familial chylomicronemia syndrome (FCS), but the pricing reset comes as Ionis prepares for a broader launch, with an FDA decision in sHTG expected by June 30.

FCS is a rare, inherited metabolic disorder caused by lipoprotein lipase (LPL) enzyme deficiency, leading to extremely high triglyceride levels.

Pricing Reset Ahead Of Larger Market Opportunity

Ionis had previously guided to a significantly lower WAC range of $10,000 to $20,000 annually for sHTG.

However, William Blair notes that the earlier-than-expected pricing adjustment reflects alignment with payer contracting cycles, as April 1 marks a key benchmark for commercial insurance budgeting.

The timing suggests Ionis is ...